Showing results (91-100 of 100) with videos related to
Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Journal of Medicinal Chemistry|December 23, 1994
Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonistsA D Palkowitz, M I Steinberg, K J Thrasher, et al.Environmental Microbiology|March 23, 2011
Microbial community structure of hydrothermal deposits from geochemically different vent fields along the Mid-Atlantic RidgeGilberto E Flores, James H Campbell, Julie D Kirshtein, et al.Applied and Environmental Microbiology|April 16, 2021
Development of Wastewater Pooled Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) from Congregate Living SettingsLisa M Colosi, Katie E Barry, Shireen M Kotay, et al.Bioorganic & Medicinal Chemistry Letters|May 3, 2005
3,3-Bisaryloxindoles as mineralocorticoid receptor antagonistsDavid A Neel, Matthew L Brown, Peter A Lander, et al.American Indian and Alaska Native Mental Health Research (Online)|July 26, 2022
Lessons on Resilient Research: Adapting the Tribal Turning Point Study to COVID-19Rachel I Steinberg, Joel A Begay, Paula M Begay, et al.Pediatric Obesity|August 30, 2025
A Randomised Controlled Trial Testing a Behavioural Intervention Program for the Prevention of Type 2 Diabetes Among American Indian Youth: The Tribal Turning Point StudyCatherine C Cohen, Dana Dabelea, Madhumita Sinha, et al.Journal of Medicinal Chemistry|November 28, 2007
(S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptorMichael G Bell, Douglas L Gernert, Timothy A Grese, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2013
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trialC Oakman, P A Francis, J Crown, et al.Nature Communications|May 23, 2019
Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expressionLodoe Lama, Carolina Adura, Wei Xie, et al.Bioorganic & Medicinal Chemistry|January 20, 2007
Azetidinones as vasopressin V1a antagonistsChristophe D Guillon, Gary A Koppel, Michael J Brownstein, et al.Pageof 10